Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib and Nivolumab in mCRPC and Endometrial Cancer
NCT03572478Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rucaparib and nivolumab in metastatic castration-resistant prostate cancer (mCRPC) and endometrial cancer (EC) (4 arms), sponsored by University of Chicago. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities at 8 weeks and Frequency of Patients With T Cell Inflammation in the Tumor at 4 weeks. Started Aug 2018; status: terminated.
02
Drugs
rucaparibnivolumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03572478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572478.